PHARMACOLOGY AND TOXICOLOGY T HE PHARMACOLOGY of interferons has been studied with human leukocyte interferon and with mouse and rabbit interferons. These have a short half-life in the blood, irrespective of the route of administration, though the most rapid clearance follows the intravenous route; intramuscular injections result in peak blood levels after 2-4 hr, lasting for 4-6 hr. With intra...

The interferon-induced enzyme 2-5A synthetase can be a sensitive indicator of activation of the human interferon system during viral infection or interferon therapy. To determine the response of the human interferon system to viral antigens, the level of 2-5A synthetase activity was monitored in peripheral blood mononuclear cells of healthy adults before and after immunization with influenza or...

The relative amounts of translatable cellular mRNAs and newly synthesized cellular proteins were examined in poly(I) x poly(C)-induced human fibroblast cells early during induction. At this time interferon and interferon mRNA synthesis are maximal and cells have not acquired their antiviral thesis are maximal and cells have not acquired their antiviral state. Translation of the mRNA from poly(I...

we aimed to compare the therapeutic effect of avonex (av), betaferon (be) & rebif (re) on the expanded disability status scale (edss) in multiple sclerosis (ms). ninety patients referring to farshchian hospital were entered in this study. the patients were divided into three equal groups: group 1 received av, group 2 received re and group 3 received be, and after 24 months, comparison was done ...

abstract introduction:  this study was performed to compare the effects of low-dose interferon beta-1(cinnovex,30 mcg) and high-dose interferon beta-1(rebif,44 mcg) on the reduction of the number and size of plaques in magnetic resonance imaging (mri) in patients with multiple sclerosis (ms). methods and materials: this historical cohort study, which was performed in 2014 in sanandaj (western p...

conclusions this study supports the idea that the ifnl3 gene is an important predictor of the response of chb patients to ifn therapy. results nine studies of 1602 chb patients receiving ifn treatment were included. under the random-effects model, patients expressing the variant rs12980275 showed a significantly increased response to ifn therapy (or = 2.85; 95% ci = 1.14 - 4.60). in the subgrou...